Open Access Open Badges Commentary

Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force

Lisa H Butterfield1, Mary L Disis2, Samir N Khleif3, James M Balwit4 and Francesco M Marincola5*

Author Affiliations

1 Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA

2 Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, WA, USA

3 Cancer Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

4 Society for Immunotherapy of Cancer and Executive Director, Inc., Milwaukee, WI, USA

5 Infectious Disease and Immunogenetics Section (IDIS), Dept. of Translation Medicine, Clinical Center, and Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA

For all author emails, please log on.

Journal of Translational Medicine 2010, 8:130  doi:10.1186/1479-5876-8-130

Published: 7 December 2010


The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.